<SEC-DOCUMENT>0001387131-15-000921.txt : 20150318
<SEC-HEADER>0001387131-15-000921.hdr.sgml : 20150318
<ACCEPTANCE-DATETIME>20150318082209
ACCESSION NUMBER:		0001387131-15-000921
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150318
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150318
DATE AS OF CHANGE:		20150318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		15708787

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_031815.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: none">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; text-transform: uppercase; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="font: bold 10pt Times New Roman, Times, Serif">FORM
8-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PURSUANT
TO SECTION 13 OR 15(d) OF THE</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-transform: uppercase; text-align: center"><FONT STYLE="font: bold 10pt Times New Roman, Times, Serif">SECURITIES
EXCHANGE ACT OF 1934<BR>
<BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date
of Report (Date of earliest event reported): March 18, 2015</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TherapeuticsMD,
    Inc.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 30pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>001-00100</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State
                                         or Other</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jurisdiction
        of Incorporation)</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission
    File Number)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(IRS
    Employer<BR>
    Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6800
                                         Broken Sound Parkway NW, Third Floor</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Boca
        Raton, FL 33487</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address
    of Principal Executive Office) (Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registrant's
telephone number, including area code: (561) 961-1900</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (<I>see</I> General Instruction A.2 below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman">&#9744;</FONT>&#9;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Times New Roman">&#9744;</FONT></FONT>&#9;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Times New Roman">&#9744;</FONT></FONT>&#9;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman">&#9744;</FONT>&#9;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: -1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
5.02.&#9;&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
March 18, 2015, the Board of Directors (the &#8220;<U>Board</U>&#8221;) of TherapeuticsMD, Inc., a Nevada corporation (the &#8220;<U>Company</U>&#8221;),
appointed Mr. Angus C. Russell and Mr. J. Martin Carroll to serve as directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mr.
Russell previously served as chief executive officer of Shire PLC, a biopharmaceutical company, from June 2008 until April 2013
and as its chief financial officer from 1999 to 2008. Prior to joining Shire, Mr. Russell served at ICI, Zeneca and AstraZeneca
PLC for 19 years, most recently in the role of vice president, corporate finance at AstraZeneca. He is a chartered accountant,
having qualified with what is now PriceWaterhouseCoopers LLP. Mr. Russell also serves as a director of Mallinckrodt PLC (NYSE:
MNK) and BioTime Inc. (NYSE MKT: BTX) and as chairman of the board of Revance Therapeutics Inc. (NASDAQ: RVNC). Mr. Russell previously
served as a director of Shire, Questcor Pharmaceuticals Inc. and InterMune Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mr.
Carroll previously served as president and chief executive officer of Boehringer Ingelheim Corp. (U.S.) from 2003 until 2011 and
as global head of strategy and development for Boehringer Ingelheim (Germany) from 2009 through 2012. Previously, Mr. Carroll
held positions of increasing responsibility with Merck &amp; Co. Inc. from 1976 to 2001, including manufacturing, international
(Japan) and marketing and sales. He left Merck serving as its executive vice president for customer marketing and sales of the
U.S. Human Health Division. Mr. Carroll also serves as a director of Mallinckrodt PLC. He previously served as a director of Accredo
Health Group Inc., Vivus Inc. and Durata Therapeutics Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Board has determined that each of Mr. Russell and Mr. Carroll is independent under the rules of the NYSE MKT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
directors of the Company, each of Mr. Russell or Mr. Carroll will receive compensation in the same manner as the Company&#8217;s
other directors, which compensation the Company previously disclosed in its definitive proxy statement on Schedule 14A, filed
with the Securities and Exchange Commission on April 17, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
are no arrangements or understandings between either of Mr. Russell or Mr. Carroll and any other person pursuant to which either
Mr. Russell or Mr. Carroll, as the case may be, was appointed as a director of the Company. Other than as described in this Current
Report on Form 8-K, since the beginning of the Company&#8217;s last fiscal year, the Company has not engaged in any transactions,
and there are no proposed transactions, or series of similar transactions, in which either Mr. Russell or Mr. Carroll was or is
to be a participant and in which any related person had a direct or indirect material interest in which the amount involved exceeds
or exceeded $120,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Also
on March 18, 2015, Mr. Randall Stanicky resigned from his position as a director of the Company. To the knowledge of the Company,
Mr. Stanicky did not resign as the result of any disagreement between himself and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
7.01.&#9;&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
March 18, 2015, the Company issued a press release announcing the appointment of Mr. Russell and Mr. Carroll to the Board, as
well as the resignation of Mr. Stanicky from the Board. A copy of the press release is furnished as exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference. The information furnished in Item 7.01 of this Current Report on Form
8-K shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
9.01.&#9;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&#9;<I>Exhibits.</I></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0">Exhibit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 11%"><FONT STYLE="font-size: 10pt"><U>Number</U></FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 85%"><FONT STYLE="font-size: 10pt"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-top: 5pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 5pt"><FONT STYLE="font-size: 10pt">Press release dated March 18, 2015.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 2in; text-indent: -1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 18, 2015 </TD>
    <TD COLSPAN="3">THERAPEUTICSMD, INC.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 7%">By:</TD>
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Daniel A.
    Cartwright</FONT></TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD COLSPAN="2">Daniel A. Cartwright</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD></TD>
    <TD>Title:</TD>
    <TD COLSPAN="2">Chief Financial Officer </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 243pt; text-align: center; text-indent: -243pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 11%">Exhibit</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 85%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><U>Number</U></TD>
    <TD>&nbsp;</TD>
    <TD><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-top: 5pt">99.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 5pt"><A HREF="ex99-1.htm">Press release dated March 18, 2015</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-8k_031815.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD 8-K</FONT></A></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit 99.1&nbsp;</FONT></P>

<P STYLE="font: 9pt/107% Sans-Serif; margin: 0 0 8pt 3.5in; text-align: center; color: Red"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/107% Sans-Serif; margin: 0 0 8pt 3.5in; text-align: right; color: Red"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><IMG SRC="image_001.jpg" ALT="">&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/107% Sans-Serif; margin: 0 0 8pt 3.5in; text-align: right; color: Red"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FOR
IMMEDIATE RELEASE</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TherapeuticsMD
appoints biopharmaceutical senior executives </B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Angus
C. Russell and J. Martin Carroll as independent directors</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>BOCA
RATON, Fla., March 18, 2015</B> &ndash; TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women&rsquo;s healthcare
company, announced today the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll,
as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of
directors.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Angus
C. Russell served as CEO of Shire PLC, a biopharmaceutical company, from June 2008 until April 2013. Russell served as the chief
financial officer of Shire from 1999 to 2008 and also served as executive vice president of global finance. Prior to joining Shire,
Russell served at ICI, Zeneca and AstraZeneca PLC for 19 years, most recently in the role of vice president, corporate finance
at AstraZeneca. He is a chartered accountant, having qualified with what is now PriceWaterhouseCoopers LLP. Russell also serves
as a director of Mallinckrodt PLC and BioTime Inc. and as the chairman of the board of Revance Therapeutics Inc. Russell previously
served as a director of Shire PLC, Questcor Pharmaceuticals Inc. and InterMune Inc.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">J.
Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. (U.S.) from 2003 until 2011. He also served as global
head of strategy and development for Boehringer Ingelheim (Germany) from 2009 through 2012 and served as chairman of the board
for a number of BI companies. Previously, Carroll held positions of increasing responsibility with Merck &amp; Co. Inc. from 1976
to 2001, including manufacturing, international (Japan) and marketing and sales. He left Merck serving as its executive vice president
for customer marketing and sales of the U.S. Human Health Division. From 1972 to 1976, Carroll served in the United States Air
Force. Carroll has previously served on the board of directors for a number of organizations, including Accredo Health Group Inc.,
Vivus Inc., Durata Therapeutics Inc., and Gwynedd Mercy College, as well as PhRMA. He currently serves as a director of Mallinckrodt
PLC.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;We
are very pleased to add two new independent directors to our board. These biopharmaceutical industry leaders have a wealth of
experience in both serving as directors and in practical senior leadership responsibilities at successful organizations,&rdquo;
said TherapeuticsMD CEO Robert G. Finizio. &ldquo;This is an exciting time in our company&rsquo;s growth and development, and
we look forward to the insight of Angus and Marty.&rdquo;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Finizio
commended the contributions of outgoing director Randall Stanicky, who currently serves as managing director of global equity
research, with a focus on specialty pharmaceuticals, at RBC Capital Markets.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;We
would like to thank Randall for his help, contributions and commitment to TherapeuticsMD as a valued board member who will be
missed,&rdquo; Finizio said. &ldquo;Randall&rsquo;s unique experience and extensive knowledge in this sector have been very helpful
as we advance our hormone therapy portfolio and gain greater leadership in the women&rsquo;s healthcare space. We sincerely thank
Randall for his tenure with us.&rdquo;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>About
TherapeuticsMD, Inc.</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD,
Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its patented
SYMBODA&trade; technology platform, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery
of bio-identical hormones
through a variety of dosage forms and administration routes. The company&rsquo;s clinical development pipeline includes two phase
3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter
vitamins under the vitaMedMD<SUP>&reg;</SUP> and BocaGreenMD<SUP>&reg;</SUP> brands. More information is available at the following
websites: www.therapeuticsmd.com, www.vitamedmd.com, www.vitamedmdrx.com and www.bocagreenmd.com.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>This
press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are
not limited to, statements relating to TherapeuticsMD&rsquo;s objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates
will or may occur in the future. These statements are often characterized by terminology such as &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo;
&ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;should,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;will,&rdquo;
&ldquo;expects,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;positioned,&rdquo; &ldquo;strategy&rdquo; and similar
expressions and are based on assumptions and assessments made in light of management&rsquo;s experience and perception of historical
trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements
in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any
such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties, many of which are outside of the company&rsquo;s control. Important
factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements
are described in the sections titled &ldquo;Risk Factors&rdquo; in the company&rsquo;s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form
8-K, and include the following: the company&rsquo;s ability to maintain or increase sales of its products; the company&rsquo;s
ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; the
length, cost and uncertain results of the company&rsquo;s clinical trials; the potential of adverse side effects or other safety
risks that could preclude the approval of the company&rsquo;s hormone therapy drug candidates; the company&rsquo;s reliance on
third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from
government authorities and health insurance companies for the company&rsquo;s products; the impact of product liability lawsuits;
the influence of extensive and costly government regulation; the volatility of the trading price of the company&rsquo;s common
stock and the concentration of power in its stock ownership. PDF copies of the company&rsquo;s historical press releases and financial
tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.</I></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>###</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Contacts</U></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Investors:</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dan
Cartwright</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
Financial Officer</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">561-961-1900</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dan.Cartwright@TherapeuticsMD.com</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Media:</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Julia
Amadio</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
Product Officer</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">561-961-1900</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Julia.Amadio@TherapeuticsMD.com</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``Q`:8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P"?^W_B_P#\
M^M__`."^/_XFJ6I>-OB=HT"3ZD]Q:1.VQ7FL8U!;&<?=ZX!KZ%KR_P".G_(H
M:?\`]A!?_1;UU4ZBE)1<4<=6E*$')3>AR%GXL^*VH6D=W9I>3V\@RDD=A&58
M>QVUT/A+6?B7<^*K"'6[>\736=O/+V2(H&QL98*".<5V?PU_Y)UHO_7`_P#H
M1KJZF=57<>5%4Z+LI.3/`?C;_P`CY8?]>,?_`*,>O?J\!^-G_(^6'_7C'_Z,
M>NL\4?&C3])OGLM'M!J,D9VO.TFR+/HN`2WUX'IFJG"4X0443"I&%2;D^IZE
M17C&E_'?==*FJZ,$@)PTMM+DK_P$CG\Z]>L+^UU2PAOK*=9[:=0\<B]"/\]J
MPG3E#XD=$*L*GPLLT50UG6M/T#39-0U.Y6"W3C)Y+'L`.I/L*\HN_CE<SW;1
M:-X?,L8Y!FD)<CU*J./S-.%*4]D$ZL(?$SV:BO*O#WQMT^^O%M=:L3IQ9MHG
M23?&#_M<`J/?GWQ7JBLKJ&4AE(R"#D$4IPE!VDAPJ1FKQ8M%<#'\26?XC_\`
M")?V2`//,7VK[1Z(6SLV^V.M9WBCXSZ;I%Z]EI-I_:4D9VR3>9LB!]%."6_0
M>YIJC-NR1+K4TKMGI]%<QI_C"!O`,'BG4XS#$T7F2)`IDV_-M`'?KBN!O_CU
M&LQ73]"9H^SW%P%8_P#`5!_G1&E.3LD$JT(I-O<]EHKQO3OCQ$]PJZEHC1PG
MK);S[RO_``$@9_.O6=+U2RUG3H=0T^X6>UF&4D7OZ@CL0>"#TI3IRA\2'"K"
M?PLMT5Y]JOQ-;3/B"GA;^R5D5IX83=&YVX$@4YV[>V[U[5G>)OC5IVF7CV>C
M6G]HNA*M.9-D6?\`9X);Z\#T)JE1F[60G7IJ]WL>I45XOI_QW<7(35=#"Q9P
MS6TOS+_P%AS^8KUG1]9L->TV/4--N5GMI.C+U![@CJ"/0TITI0^)#A5A/X67
MZ*9--%;P23SR)'%&I9W<X50.22>PKRC6_C?:PWAM="TQ[X`[1/*Y17/^RH!)
M'UQ]*4*<I_"ASJ1A\3/6J*\<L/CD\=Z(-;T)H$S\S0.=R?\``&`S^=>L:9J=
MEK.G0W^GW"7%K,,I(O?U'L0>"#R*)TY0^)"A5A/X66Z*X'7?B2VB^.[7PT-)
M$PGD@3[1]HV[?,(&=NT],^O-=]2E%Q2;ZE1FI-I=`HK+\1ZN=`\.WVJB#SS:
MQ&3RM^W=[9P<?E63X%\8GQIHUSJ!L!9^3.8=@F\S.%5LYVC^]^E'*^7FZ!SI
M2Y>IG?$;Q]=>"&TX6UC#=?:Q*6\QRNW;MZ8_WJ[+3KIKW3+2[90K3PI(5!R`
M64''ZU\U^/?'A\<O8DZ<MG]C$@XG\S?NV_[(Q]W]:ZRP^.;6.G6UI_PCR/Y$
M2Q;OMN-VT`9QLXZ5T2P\N166O4Y8XF//*[TZ'N)Z&O(?A['X]7Q<A\0?VK_9
M_E29^TOE-W;OUKTW0-4_MOP_8:IY(A^UP+-Y8;=MR,XS@9_*N3\)?$AO%'BN
M\T0Z4+86Z2/YPN-^[8X7[NT8SG/6LH<R4E8VGRN46W_P3O:*KWU_:Z98S7M[
M.D%M"NZ21S@**\GU?XZ0I=&'1=(:X3.%EN)-F[Z(`3CZD'VJ84Y3^%%3JPA\
M3/8**\:TWX[#[4(M7T0QQYPTEM+EE_X`P'\Z]8TK5K#6].BO]-N4N+:0?*Z_
MR(Z@^QYHG3E#XD$*L)_"R[17!>-?BEIOA*[.GQ6[7^H*`7B5]B19Y&YL'G'.
M`#^%<C'\=KR*13=^'4$3<C;<%3CVRO-5&A.2ND3+$4XNS9[77(?$+6]0T+2+
M6?3IQ#))<;&.Q6R-I/<'TJUX3\<:1XQAD.GM*D\(!E@F3#(#T.1D$<=C6)\6
M?^0!8_\`7U_[(U.E&U11DC'&U+86<X/IO]QK^!_%'_"1Z45N&7^T+?Y9@!C>
M.S@>_?W'TKJ:\<N[.Y\$ZCI/B"P4M97,*>8F3C)4%T/UZCW'M7K=C>V^I6,-
MY:N'@F0.C>W^-%:"3YH[,C`UY3C[*K\<?Q71EBO-O'/CN\T[5%T[1IUC:$9N
M)=@;YC_",C''?W/L:Z?QEXD3PYHCRHP^V392W7W[M]!U_(=Z\NU'PX^G^"H=
M9O0YOKVZ7&\\K&58Y/NQ&?R]ZO#TU?FE\C#,L3-1=.B]4KM]E_FSV/0;F:]\
M/Z==7#;YIK:-W;`&6*@DX%>;)XB\::IX@U#3])N5D-O+)A#'$-J!]HY(^E>A
M^%_^14TG_KSB_P#017"^`O\`DH6O?2;_`-'"BG9<[MM_F5B7*7L(J37-O9_W
M25I/B="-Y1)`.J@0']!S4FG_`!*N;2\%GXDTUK9^\D:,I7W*'G'N#^%>CUF:
MYH-CX@T]K6\C!X/ER`?-&WJ#_G-2JL):2C]QI+"5J:YJ-1W[2U3+:WML]A]N
M297MO+\P2)R"N,Y&*IV&N07]Y+:K%+')'N!W8QE2`1P>HR.*X#P/>W&B^([S
MPGJ)#PR%U16^[O`SQ[,O/Y>IKT:UTNUM+@SQJYD*[<LQ.!W_`!.!SU.!4S@H
M-I_(TP]>=>*DM+:->9=HHHK([`KR_P".G_(H:?\`]A!?_1;UZA7E_P`=/^10
MT_\`[""_^BWK6A_$1CB/X4CI?AK_`,DZT7_K@?\`T(UU=<I\-?\`DG6B_P#7
M`_\`H1KJZFI\;+I_`O0^?OCCD^-K,`9/]GIQ_P!M)*]=\'>#M.\*:-!;PP1-
M>%`;BY*C?(_?GJ%]!_7->2_&W_D?+#_KQC_]&/7OU;59-4H(YZ,4ZTV</\3?
M"FGZUX3O[TV\:7]E"T\4ZJ`V$&2I/<$`CZ\U@?`K4)9M!U.P=F9+:X5XP3]T
M.#D#\5)_$UWWBW_D3-<_[!\__HMJ\U^`G_'OKW^_!_)Z47>C)/H.22Q$6NJ9
MD?$2ZN_&7Q.M?#-O*5@MY%MU]`S`-(^.^!Q_P'WKVG1="T[P]IT=CIMLD,*#
M!('S.?5CW/O7SUX@T:6^^,%]I;7GV.2ZOB$G8'Y=XW+T]<@#ZUV'_"E=9_Z&
ML_\`?M__`(NM*D8\L8N5E8SI2ESRDHW=SH_BMX/L]8\,W6K0P(FI6,9F\U1@
MR1KRRMZ\9(]Q[FHO@QKTFJ>$Y=/N)"\NG2"-">3Y3#*#\"&`]@*Y]O@GJ[J5
M;Q5N4C!!B<@_^/UU_P`//`,_@A]1,VH1W8NQ&`$B*;=N[U)S][]*B3@J7+S7
M[%Q4W54^6W<\:\<M=+\3]6^Q-(MRUSLC\HX8EE"X!'KG'XU[%X/^%^BZ!I\3
MZA9P7^ILH,LLRAT0_P!U%/``]>I_0>>F!+C]H;RY`"HU#?@^JQ[A^H%>_55:
M;48Q786'IIRE)]RI<:997.ERZ9);1_8I8S$\*#:NTC!`QC'X5B)>^"O"W^AI
M<Z-ISIP8@\:N/KW_`#KDOC/XKO-&T^TTFPF:"2]#O-*APPC7`V@]LD]?;WJE
MX7^"NGR:7;W>O7-R]S,@<V\+!%CR,X)P23Z\@?SK.,$H<TW9,TE4;GRPC=HZ
M'Q0O@GQEHUS;KJ>D/?B)FMYDGC$B.!D=\D9ZBN9^`VH2O%K.G,Y,*&.>-3V9
MMP;_`-!7\JUM2^"?AIK:22VN;^V=$)'[Q77@=P1G]17.?`8YU;6#_P!.\?\`
MZ$:T]WV4E%W,O>5:+DK>ASWQ,MIKWXL7UI;C,\\EO%&,XRS1H!^IKV[PEX)T
MKPEIT<5M!')>%1Y]VRY>1N^#V7T`_GS7D7BVZBLOCRES.0(HKRT9V;HHV1Y/
MX=:^@J5:34(KI8>'C%SG+K<Q?$?A72O%&G26FHVR,Q4B.=5`DB/8J?Z=#WKQ
MSX87UYX6^(]SX:N7)BG>2WD7HOF)DJX'N%(]]P]*]]KY_CD75OV@]]JQVC4.
MH_Z9)AOP^0TJ+;C*+VL5724HR6]SHOCCX@EMK*QT&"0J+G,]P%/)13A5/L3D
M_P#`178>`?!=GX5T*W)MT.IS1A[F<@%MQ&2H/91TX],UYC\=+>1/%>GW+*?*
MDL@BMZE78D?^/+^=:,'P;U6YMXIX?%P>*1`Z,J.001D$?/56C[**O:YFI2]M
M)\M['J'B?PQI_BK2)K&]A0N5/DS[?GB;LP/]._2O*O@QJMUIOB74O#-TQV$.
MX3.0DT9VMCZC_P!!%6O^%*ZS_P!#6?\`OV__`,76MX/^%%WX8\4VVL2ZQ%<B
M(.&C$)4MN4CJ6/KFDG",''FN4U4E4C+EL<MXY_Y+GIG_`%\67_H2U[S7@OCL
MA/CCIK,<*)[,Y/IO%>]5-;X8>A=#XI^IS'Q$_P"2>ZY_U['^8KE?@7_R*&H?
M]?[?^BTKI_B3,D/P[UII&P#!L'U9@!^I%<Q\"_\`D4=0_P"O]O\`T6E*/\%^
MH2_WA>C,+X\6\,$FA&&&./<MQG8H&?\`5^E>K:%8V9\/:83:0$FUB_Y9C^X*
M\N^/OW]`_P!VX_\`:=>LZ#_R+NF?]>D7_H`IS?[J/S"FOWT_D7U140(BA5`P
M`!@"O"?A/_R575_^N-Q_Z.6O=Z\(^$__`"575_\`KC<?^CEI4O@GZ!6_B0]2
M3XM:O>Z_XRL_"5BQ\N-XU*9P'FDQ@GV`(^F37JGA;P?I7A/38[:R@1I]H\ZY
M91YDK=R3V'H.@KR#6YTTG]H!;J[^6$WD+;FZ!6C5<_0$_I7OU.JW&$8K:PJ*
M4IRD][F)XC\*:1XHL'MM2M49B,1SJ`)(SZJW].A[U'X1\)V7@_15T^T9I'9M
M\\[#!E?&,X[#C`'\SDUOT5CS2MRWT.CDCS<UM3YST+4=-T;XN:C=>)X\J+JX
M`>1"PBE+_*Y'IC.#VR#[U[_')IFNV&8WM+^SD&."LJ-_,5@>+/AYH?BYQ/=Q
MR6]Z!M%S;D!B.P8$$-^//O7F>H_"/Q/X<9[[P[JAN609Q`S038]AG#?G^%=#
M<*MG>S.9*I1NK77XGL>B>&](\.K<KI-DELMS+YL@4DY.,8&>@'8=!DURGQ9_
MY`%C_P!?7_LC51^%?CZ_\227.CZQB2^MX_-2<+M,B`@$,.FX$CD=<^W-[XL_
M\@"Q_P"OK_V1JF$91K)2W,L9*,L'-QVM^J.ECTNWUGP=;6%TN8IK2,9'53M&
M"/<'FN'\):S+X/UJ[\.ZW*([8$O'*Q^53C.1_LL/U]R:]%T7_D`Z=_U[1_\`
MH(KG_'/A$^([6*:T"+J$)"JS<!D)Y!/MG/Y^M*$E=PELQ8BC/EA7H_'%+YJR
MT.8TFWF^('C"35;N-AI5H0$C8<$#E4_'JWY=Q6U\5O\`D5[;_K\7_P!`>NKT
M72+?0])@T^V'R1CYF/5V/5C]37*_%;_D5[;_`*_%_P#0'JHSYJL;;+8RJT'2
MP51SUE)7;\]/R.D\+_\`(J:3_P!><7_H(KA?`7_)0M>^DW_HX5W7A?\`Y%32
M?^O.+_T$5Q/@6":/Q_KCR0R(C";#,A`/[T=Z4=JG]=2JJ][#^O\`[:>F444U
MW6-&=V"HHRS$X`'K7.>H>6^+A]F^*FDRP\/(UNS8[G>5_D!7JE>3Z9(?%_Q1
M-_&"UG:-YBMCC:G"?FW/Y^E>L5O7T48O=(\[+_>E5J+9RT^04445@>B%>7?'
M7_D4-/\`^P@O_HMZ]1J"ZLK2^C$=W;0W"*=P6:,.`?7!JZ<N62D14ASP<>YS
M?PU_Y)UHO_7`_P#H1KJZC@@AMH5A@B2*)!A4C4*H^@%25,G=MCBN6*1X!\;2
M!X\L,G_EQC_]&/7O]5+K2M.O91+=V%K/(!M#RPJQ`],D5;JYU.:,8]B(4^64
MI=S&\7?\B9KG_8/G_P#1;5YI\!"#;Z]S_%!_)Z]BDC2:)HY$5XW!5E89#`]0
M14%II]E8!Q9V=O;A\;O)B";L=,X'-$9V@X]PE3O44^QYK\6/`=YK#Q>(-%C9
M[^W0+/%'P\BCE67U9?3J1C'0`Y?A_P"-ZVUFMMXBT^XDN8AL:>V"Y<C^\C$8
M/K@_@*]GK+O_``WH>J3>=?Z/8W,O_/2:W5F_,C-5&K%QY9JY,J4E+FINUSRC
MQ!\9[G5(O[.\+Z;<17$_R+-*`TO/9$7//OD_2O2?!$6OP^%[5/$DBO?`<=W"
M=@Y[OZG^9R3I:?H.D:2S-IVEV=HS#!:"!4)^I`K0I3G%KEBK#A":?-.5_P`C
MP6$C_AHL\_\`+ZW_`*)->]54&EZ>+S[8+&V^U9W>?Y*[\XQG=C/2K=*I/GMY
M(=*GR7\V>6?&?PI>ZQ86FKV$+3O9*Z3Q(,L8S@[@.^"#GZ^U9_ACXUV5OI$%
MIKMI=&YA01^?;A660`8!()!!]>OX=*]CK(N_"OA^_N&N+O1-.GF;EI)+9"Q^
MIQS51J1Y>6:O8F5*7/SP=KGE^N_$K4O&D,VA>$-*N@9XR)[B7`98\?-T)"@C
MC<3WP!G%5/@,0=7UG!_Y=X__`$(U[19:;8Z=;FWL;.WMH3UCAB"+^0%%IIEA
M8,S6=C;6[,,,88E3(]\"FZL>1PBB51ESJ<I7:/GKXBV$FJ_%^[T^%E66ZEMX
M4+]`S1H!GVYKH=%^)^K^#6&@^+-,N)GMAL24$"7:.!UX<>C`C\:SO$__`"<!
M;_\`7_9?^@QU[I?Z5I^JQ"+4;&VNXQR%GB5P/ID5K4FE&*DKJQC2A)SG*+L[
MGCOB3XV27UF]GX>L)[>68;/M$Y&]<\?*JYY]#G\*VOA+X#N]%\S7]7C:.]N(
M]D$#_>C0G)9O1C@<=0,YZX'?V'AO0]+F\ZPT>QM9?^>D-NJM^8&:U*RE57+R
MP5C>-&7-SU'=HY#XB>#O^$P\/^3`434+9C+;.W0G'*$]@?Y@>E>:>%?B9J7@
ME?\`A'_$>G7$D5J=J#[LT(_NX/#+Z<CCN1C'O54M0TC3=614U'3[6[5?NB>%
M7Q],CBE"HE'EDKH<Z3<N>#LSR_5?CM8+:,-(TJY>Y(PK7>U44^N%8D_3CZUN
M?#";QA>6MW?^(Y#]DN6\RV2=,2Y/4@?PIZ`CW&!UZJS\*^']/G6>ST33X)E^
M[)';(&'T.,BM>B4X<MHH<:<^;FG+[CQ[XT>$[NZDM_$=A"\HAB\JZ$?+(H)*
MO@=AD@GMQVSB#P_\<4ATZ.#7-/GFN(U"_:+8K^]QW*DC!]<'\NE>T5C3^$?#
M=S.TT^@:9)*QRSM:H23[\<TXU8N/+-7L3*C)3<Z;M<\5\6>+=;^(FFW36%@U
MIH6G*9YV9\[V'3<W3//"CZGMCLO@5_R*&H?]?[?^BTKTA-/LH[+[$EI`MIC;
MY`C`3'IMQBG6ME:6,9CM+6&W1CN*PQA`3ZX%$JJ<.1*P0HM3YV[L\O\`CCHM
MS>Z-IVJ01M)'9.ZS!1G:KA?F/L"N/QK+T'XV6VG>'K:ROM*GENK:%8E>*1=L
M@48!.>0<#WKVL@$$$9![&L;_`(1'PWY_G?V!I?FYSO\`LD><^O2B-6/)RS5[
M!*E/G<X.URQH.IG6O#^GZHT0A-W`DWEAMVW<,XSQFO&/A.1_PM75^?\`EC<?
M^CEKW=5"J%4``#``[55M]+T^TG:>VL;:&9@0TD<2JQSR<D#-3&HHJ2MN7.FY
M.+OL<%\5/`,OB>UCU33$#:G:H4:+IY\?7`_V@<X]<D>E<IX7^,-YH5LNE>)+
M"XN&MOW8F7Y9E`_A=6QDCUR#ZY/->YUG:CH.CZNZOJ.EV=VZC`:>!7('L2*<
M:JY>6:NB9T7S<\'9GDVO_&V6]@^Q^&].GBGF^19[@!G!/'RHN03Z9/X&NX^'
MUMXILO")&OR>==G+6L4['S57'"R/SU/L2!U]!T&G^'M%TF0RZ?I-E:R$8+PP
M*C?F!FM*E.<;<L4.%.:ES3E<\-M_B?XM\):I-:>*M,:=9)&=58>6R`GI&PR&
M4=NOUK;O?CMI"V3FQTJ^>ZQ\BS[%0'W(8G'X?E7J-U:6U]`8+NWBN(CUCE0,
MI_`UEQ>$/#4$PEB\/Z6DBG(9;1`1].*KVE-ZN/W$^SJK2,M/,\W^#7A_46U+
M4/%-_&T:72,D.Y=OFEV#LX'IP,>N3Z5T7Q:_Y`%C_P!?7_LC5Z!TJ&XM+>[0
M)<V\4R@Y`D0,`?QI>U_><[1-7#<U!T4]^I7T3_D`Z=_U[1_^@BKU(JJB!$4*
MJC``&`!2UDW=W.B*M%(*X3XK_P#(KVW_`%^+_P"@/7=U%<6MO=QA+F".9`<A
M9$##/KS54Y<LE(SQ-)UJ4J:=KGG6C?$S2-.T6QLI;2^:2W@2)BBH02`!QEJO
M?\+8T3_GSU#_`+X3_P"+KKO[&TO_`*!MG_WX7_"C^QM+_P"@;9_]^%_PK1SI
M-WY7]YRQHXR*4546G]W_`()QLOQ:TE4)AL+UW[!]BC\PQK'N=1\5>/\`%K9V
M9LM-8_,V2$(_VG/WOH!^%>FQZ5IT3AX["U1AT985!'Z5;H52$=8QU\PEA:]7
MW:U33LE:_P`S&\-^'+3PUIHM;?YY6^::8C!D;^@'8?\`US6S116+;D[L[H0C
M3BHQ5D@HHHI%!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M'@'B?_DX"W_Z_P"R_P#08Z]_HHKHK[0]#EP_Q3]0HHHKG.H****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
,@`HHHH`****`/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
